Cyclarity Therapeutics Reports Safety Data for 7-Ketocholesterol Clearance

Cyclarity Therapeutics has been processing safety data from a phase 1 safety trial of a cyclodextrin drug to bind 7-ketocholesterol, a toxic form of oxidized cholesterol that contributes to a range of conditions. The company is initially focused on atherosclerosis, the formation of fatty plaques that obstruct blood vessels and ultimately rupture to cause a...

Raccontata dafightaging.org